Fig. 6.

PPD/polyIC led to the regression of PSMA-overexpressing tumors grown in NOD/SCID mice that were engrafted with human PBMCs. (A) Schematic representation of the treatment schedule. Gray dots indicate PPD/polyIC injections; black dots indicate PBMC injections. (B) Effect of PPD/polyIC on PC3-PSMA tumors. PC3-PSMA cells (4.6 × 10⁶) were inoculated s.c. into male NOD/SCID mice. On day 0, mice bearing tumors of ∼100 mm³ in size were randomized and divided into four groups (seven mice per group). Mice were injected with PPD/polyIC alone, PBMCs alone or PPD/polyIC and PBMCs as shown in A. The graph shows means plus SEs (***P ≤ 0.001, PPD/polyIC plus PBMC treatment vs. untreated mice; **P ≤ 0.01, PPD/polyIC plus PBMC treatment vs. PPD/polyIC alone).